retatrutide clinical trials obesity ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial New GLP-1 obesity drug, retatrutide,

Furthermore, long-term fracture risk, bone microarchitecture changes, and implant survival in GLP-1 agonist users remain poorly studied

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A

Individuals with type 2 diabetes were excluded from this particular trial, meaning the results reflect outcomes in adults with obesity or overweight but without diabetes

No water restriction

The conclusion: marketing claims substantially exceeded the available evidence

The guarantee length and return procedure shown across brand materials (60 days on individual package tiles and the dedicated refund policy, 180 days in a separate order-page banner, purchase-date language in one place and delivery-date language in another, and two differently described return procedures) do not fully agree